Cyclerion Therapeutics, Inc.

NasdaqCM CYCN

Cyclerion Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2024

Cyclerion Therapeutics, Inc. EBITDA Margin is NA for the Trailing 12 Months (TTM) ending September 30, 2024. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Cyclerion Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2022 was -9,957.62%, a -458.73% change year over year.
Cyclerion Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2021 was -1,782.18%, a 26.47% change year over year.
Cyclerion Therapeutics, Inc. EBITDA Margin for the Trailing 12 Months (TTM) ending September 30, 2020 was -2,423.63%.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

NasdaqCM: CYCN

Cyclerion Therapeutics, Inc.

CEO	Dr. Regina Graul Ph.D.
IPO Date	March 18, 2019
Location	United States
Headquarters	245 First Street
Employees	1
Sector	Healthcare
Industries Pharmaceuticals Biotechnology Clinical Trials Drugstores & Retail Pharmacies

Description

Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of medicines for serious central nervous system (CNS) diseases. Its lead product candidate is CY6463, a CNS-penetrant, soluble guanylate cyclase (sGC) stimulator that is in Phase IIa trials for the treatment of mitochondrial encephalomyopathy, lactic acidosis, and stroke-like episodes, as well as Alzheimer's disease with vascular pathology; and Phase 1 trials diagnosed with schizophrenia in adults. It is also developing Praliciguat, an orally administered systemic sGC stimulator, which is in Phase II studies to treat resistant hypertension and diabetic nephropathy; Olinciguat, an orally administered vascular sGC stimulator that is in Phase II studies for the sickle cell disease; and CY3018 for the treatment of disorders of the CNS. It has license agreement with Akebia Therapeutics, Inc. for the development, manufacture, medical affairs, and commercialization of pharmaceutical products, including pharmaceutical compound, and other related products and forms. The company was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years